Evidence map›Paper›PMID 34975874›Full record

ReviewFrontiers in immunology2021

Fibrocytes: A Critical Review and Practical Guide.

James W Reinhardt, Christopher K Breuer

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Circulating Fibrocytes: Cellular Mediators of Tissue Fibrosis.International journal of molecular sciences · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. CD45+/ Col I+ Fibrocytes: Major source of collagen in the fibrotic lung, but not in passaged fibroblast cultures.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

James W ReinhardtCenter for Regenerative Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.
Christopher K BreuerCenter for Regenerative Medicine, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.

Funding

Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular GraftsR01HL098228 · NHLBI · YALE UNIVERSITY · PI BREUER, CHRISTOPHER KANE · 2010 to 2018
$3.6M
Development of an Improved Vascular Graft for Use in Congenital Heart SurgeryR01HL128847 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BREUER, CHRISTOPHER KANE · 2016 to 2019
$2.8M
Computational Model Driven Design of Tissue Engineered Vascular GraftsR01HL128602 · NHLBI · YALE UNIVERSITY · PI BREUER, CHRISTOPHER KANE, HUMPHREY, JAY D. · 2015 to 2018
$2.2M
NHLBI NIH HHS R01 HL098228NHLBI NIH HHS R01 HL128602NHLBI NIH HHS R01 HL128847
6 · The paper itself

Abstract

Fibrocytes are hematopoietic-derived cells that directly contribute to tissue fibrosis by producing collagen following injury, during disease, and with aging. The lack of a fibrocyte-specific marker has led to the use of multiple strategies for identifying these cells

Indexed as

AnimalsCells, CulturedCollagen Type IDisease Models, AnimalFibrosisHumansMesodermPrimary Cell CultureStromal CellsCollagen Type Ibone marrow chimeracollagenfibrocyteslineage tracingmyofibroblasts

Identifiers

PMID34975874
PMCPMC8718395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.